CHANCE PHARMACEUTICALS
Chance Pharmaceuticals provides, discovers, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and central nervous system disorders.
CHANCE PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.chancepharmaceuticals.com
Status:
Active
Total Funding:
51.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Font Awesome Mobile Non Scaleable Content Nginx Apple Mobile Web App Capable DigiCert SSL Encryption Everywhere Alibaba Baidu Analytics
Current Employees Featured
Founder
Investors List
Fortune Venture Capital
Fortune Venture Capital investment in Series C - Chance Pharmaceuticals
HEDA BioVenture
HEDA BioVenture investment in Series C - Chance Pharmaceuticals
Lapam Capital
Lapam Capital investment in Series C - Chance Pharmaceuticals
China Merchants Zhiyuan Capital Investment
China Merchants Zhiyuan Capital Investment investment in Series C - Chance Pharmaceuticals
Shenzhen Guozhong Venture Capital Management
Shenzhen Guozhong Venture Capital Management investment in Series C - Chance Pharmaceuticals
Yipinhong Pharmacy
Yipinhong Pharmacy investment in Series B - Chance Pharmaceuticals
Delian Capital
Delian Capital investment in Series A - Chance Pharmaceuticals
Shenzhen Guozhong Venture Capital Management
Shenzhen Guozhong Venture Capital Management investment in Series A - Chance Pharmaceuticals
Kaitai Capital
Kaitai Capital investment in Series A - Chance Pharmaceuticals
Delian Capital
Delian Capital investment in Angel Round - Chance Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-30 | Hangzhou Chance Pharmaceuticals Appoints Guobao Zhao as Senior Vice President |
Official Site Inspections
http://www.chancepharmaceuticals.com
- Host name: 180.163.141.185
- IP address: 180.163.141.185
- Location: China
- Latitude: 31.0449
- Longitude: 121.4012
- Timezone: Asia/Shanghai
More informations about "Chance Pharmaceuticals"
畅溪制药——将全新的吸入药物带给中国和世界
畅溪制药是一家处于临床阶段的 创新型生物制药公司 ，聚焦于呼吸系统、中枢神经疾病等严重影响人类日常生活质量的疾病，专注于创新型吸入药物的发现、开发和商业化。. 畅溪制药是由一群充满激情和富有业界经验的行业专家于2015年 …See details»
Chance Pharmaceuticals - Crunchbase Company Profile …
Chance Pharmaceuticals provides, discovers, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and …See details»
Chance Pharmaceuticals 畅溪制药 | LinkedIn
Chance Pharmaceuticals 畅溪制药 | 61 followers on LinkedIn. A clinical-stage biotech company focusing on discovering, developing and commercializing inhalation therapies. | Chance ...See details»
Chance Pharmaceuticals Completes Series C+ Funding to Advance ...
HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals ("Chance"), a clinical-stage biotechnology company focusing on discovering, developing, and …See details»
Chance Pharmaceuticals - Craft
Chance Pharmaceuticals is a biotech company focusing on discovering, developing and commercializing inhalation therapies. It provides, discover, develops, and commercializes …See details»
Chance Pharmaceuticals - PitchBook
Chance Pharmaceuticals General Information Description. Developer of generic drugs created to cure chronic obstructive pulmonary disease. The company's drugs are provided in dry powder …See details»
Overview, News & Similar companies - ZoomInfo.com
View Chance Pharmaceuticals (www.chancepharmaceuticals.com) location in Zhejiang, China , revenue, industry and description. Find related and similar companies as well as employees …See details»
Chance Pharmaceuticals - Products, Competitors, Financials, …
Chance Pharmaceuticals is a biopharmaceutical company specializing in innovative pulmonary drug delivery. Use the CB Insights Platform to explore Chance Pharmaceuticals's full profile.See details»
Chance Pharmaceuticals Secures $30 Million Series C Funding
Hangzhou, China, October 11, 2021 (GLOBE Newswire) — Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and …See details»
Chance Pharmaceuticals Secures $30 Million Series C Funding to …
HANGZHOU, China, Oct. 11, 2021 -- Chance Pharmaceuticals , a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation therapies for …See details»
Chance Pharmaceuticals Completes Series C+ Funding to
HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals ("Chance"), a clinical-stage biotechnology company focusing on discovering, developing, and …See details»
Chance Pharmaceuticals Completes Series C+ Funding to
Jan 4, 2022 [email protected] + 86 571-8630-9565. Goby Global Bob Ai [email protected] + 1 646-389-6658 ...See details»
Hangzhou Chance Pharmaceuticals Announces NMPA Acceptance …
HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and …See details»
NEWS CENTER - chancepharmaceuticals.com
Hangzhou, China, September 30, 2021 (GLOBE Newswire) — Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, …See details»
Acorda Therapeutics Inc - Acorda Therapeutics and Chance ...
May 8, 2023 Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply …See details»
获批 | 畅溪制药首个改良新型吸入粉雾剂CXG87的临床试验获得批准
2023 年 4 月 12 日，杭州畅溪制药有限公司（简称“畅溪”），一家专注于创新型吸入给药疗法开发的公司，宣布 中国国家药品监督管理局（ nmpa ）已正式批准其首款改良新型吸入粉雾剂 …See details»
Chance Pharmaceuticals Secures $30 Million Series C Funding
Oct 11, 2021 [email protected] + 86 571-8630-9565. Solebury Trout Bob Ai [email protected] ...See details»
Chance Pharmaceuticals and Acorda Therapeutics Announce …
HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply …See details»
Acorda Therapeutics and Chance Pharmaceuticals Announce …
May 8, 2023 PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have …See details»
Chance Pharmaceuticals and Acorda Therapeutics Announce …
May 8, 2023 Under the terms of the agreement, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million upon regulatory approval, …See details»